Cited 0 times in
First-line pembrolizumab (pembro) with or without lenvatinib (lenva) in patients with advanced urothelial carcinoma (LEAP-011): A phase 3, randomized, double-blind study.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 신상준 | - |
dc.date.accessioned | 2023-06-02T00:54:37Z | - |
dc.date.available | 2023-06-02T00:54:37Z | - |
dc.date.issued | 2022-02 | - |
dc.identifier.issn | 0732-183X | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/194522 | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | American Society of Clinical Oncology | - |
dc.relation.isPartOf | JOURNAL OF CLINICAL ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | First-line pembrolizumab (pembro) with or without lenvatinib (lenva) in patients with advanced urothelial carcinoma (LEAP-011): A phase 3, randomized, double-blind study. | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Yohann Loriot | - |
dc.contributor.googleauthor | Petros Grivas | - |
dc.contributor.googleauthor | Ronald De Wit | - |
dc.contributor.googleauthor | Arjun Vasant Balar | - |
dc.contributor.googleauthor | Arlene O. Siefker-Radtke | - |
dc.contributor.googleauthor | Jakub Zolnierek | - |
dc.contributor.googleauthor | Tibor Csoszi | - |
dc.contributor.googleauthor | Sang Joon Shin | - |
dc.contributor.googleauthor | Se Hoon Park | - |
dc.contributor.googleauthor | Vagif Atduev | - |
dc.contributor.googleauthor | Mahmut Gumus | - |
dc.contributor.googleauthor | Yu-Li Su | - |
dc.contributor.googleauthor | Saziye Burcak Karaca | - |
dc.contributor.googleauthor | Hernan Cutuli | - |
dc.contributor.googleauthor | Mehmet Nahit Sendur | - |
dc.contributor.googleauthor | Calvin Jia | - |
dc.contributor.googleauthor | Karen O'Hara | - |
dc.contributor.googleauthor | Sonia Franco | - |
dc.contributor.googleauthor | Nobuaki Matsubara | - |
dc.identifier.doi | 10.1200/JCO.2022.40.6_suppl.432 | - |
dc.contributor.localId | A02105 | - |
dc.relation.journalcode | J01331 | - |
dc.identifier.eissn | 1527-7755 | - |
dc.identifier.url | https://ascopubs.org/doi/10.1200/JCO.2022.40.6_suppl.432 | - |
dc.contributor.alternativeName | Shin, Sang Joon | - |
dc.contributor.affiliatedAuthor | 신상준 | - |
dc.citation.volume | 40 | - |
dc.citation.number | 6_suppl | - |
dc.citation.startPage | 432 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CLINICAL ONCOLOGY, Vol.40(6_suppl) : 432, 2022-02 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.